Short answer
Assembly Biosciences Inc (ASMB) filed an 8-K current report with the SEC on November 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results announced for the quarter ended September 30, 2026.
Assembly Biosciences Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 financial results announced for the quarter ended September 30, 2026
- Detailed results and management commentary available in Exhibit 99.1, relevant for assessing cash runway and clinical funding ability
Item EX-99.1 · Exhibit EX-99.1
- Cash, equivalents and marketable securities $314.3M plus $75M Gilead fee, extending projected runway into 2029
- 40% U.S. HSV program cost and profit share increases future commercial upside and development spending exposure
- ABI-6250 Phase 2 HDV dosing underway, with cholestatic liver disease Phase 2 targeted for Q1 2027
- Q3 net loss widened to $20.3M, or $0.93 per share, from $9.2M, or $0.72 per share
- Collaboration revenue fell to $3.0M from $10.8M, while R&D expense rose to $20.2M from $16.6M
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Assembly Biosciences Inc 8-K filings
Get the next ASMB 8-K as it lands
Follow ASMB for push alerts, or ask the research agent what this filing means.